The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased ...
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in ...
Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings ...
While SARS-CoV-2 is now a familiar threat, the virus isn’t neatly seasonal. It still circulates year-round, humming in the ...
CLEVELAND, Ohio — Former President Donald Trump is wildly popular among Ohio Republicans. And voters’ loyalty and Trump’s willingness to “put his shoulder to the wheel” for unknown candidates made a ...
The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday ...
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for use in people ages 50 to 59 years old thanks to recent Food and Drug ...
France’s government faces its highest borrowing costs this year after Emmanuel Macron’s shock decision to call a ...
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer ...
The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. Engadget ...
Happy Monday! One of your Morning Dispatchers has received some flak during recent Dispatch editorial meetings for wearing ...
US FDA approves GSK’s respiratory syncytial virus vaccine, Arexvy for adults aged 50-59 at increased risk: London, UK Monday, June 10, 2024, 10:00 Hrs [IST] GSK plc announced th ...